Td Asset Management Lowered Its Turquoise Hill Res LTD (TRQ) Holding; Cytokinetics Has 1.39 Sentiment

January 14, 2018 - By Marie Mckinney

Td Asset Management Inc decreased Turquoise Hill Res Ltd (TRQ) stake by 6.14% reported in 2017Q3 SEC filing. Td Asset Management Inc sold 253,800 shares as Turquoise Hill Res Ltd (TRQ)’s stock declined 20.46%. The Td Asset Management Inc holds 3.88 million shares with $11.97M value, down from 4.13M last quarter. Turquoise Hill Res Ltd now has $7.08B valuation. The stock increased 1.71% or $0.06 during the last trading session, reaching $3.57. About 1.62M shares traded. Turquoise Hill Resources Ltd. (NYSE:TRQ) has declined 2.47% since January 14, 2017 and is downtrending. It has underperformed by 19.17% the S&P500.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $476.88 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

Bvf Inc Il holds 2.29% of its portfolio in Cytokinetics, Incorporated for 1.24 million shares. Ironwood Investment Management Llc owns 110,512 shares or 1.13% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 0.47% invested in the company for 227,990 shares. The United Kingdom-based Lansdowne Partners (Uk) Llp has invested 0.4% in the stock. Pinnacle Associates Ltd, a New York-based fund reported 1.01 million shares.

Ratings analysis reveals 100% of Cytokinetics’s analysts are positive. Out of 2 Wall Street analysts rating Cytokinetics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $21.0 while the high is $22.0. The stock’s average target of $21.50 is 142.94% above today’s ($8.85) share price. CYTK was included in 2 notes of analysts from December 16, 2016. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Overweight” rating given on Friday, December 16 by Cantor Fitzgerald. The rating was upgraded by Needham to “Strong Buy” on Monday, February 6.

The stock increased 0.57% or $0.05 during the last trading session, reaching $8.85. About 181,252 shares traded. Cytokinetics, Incorporated (CYTK) has risen 88.33% since January 14, 2017 and is uptrending. It has outperformed by 71.63% the S&P500.

Analysts await Cytokinetics, Incorporated (NASDAQ:CYTK) to report earnings on February, 15. They expect $-0.71 earnings per share, down 543.75% or $0.87 from last year’s $0.16 per share. After $-0.60 actual earnings per share reported by Cytokinetics, Incorporated for the previous quarter, Wall Street now forecasts 18.33% negative EPS growth.

Since January 1, 0001, it had 0 insider buys, and 12 insider sales for $2.85 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News